Best CGM for Type 2 Diabetes in India (2026)

What should you look for in a CGM for type 2 diabetes?

Sticker price is only part of the story. Because sensors are replaced on a schedule, the figure that usually matters most is cost per day, which depends on both the sensor price and how many days it lasts. Also weigh how often the device reads, the alerts it offers, and whether it is officially sold and regulated in India.

Alerts differ between systems. All of the devices here can warn you when glucose crosses a threshold you set. Some go further: the Dexcom G7 adds a predictive low alert (“Urgent Low Soon”) and can share readings with up to 10 followers via Dexcom Follow, and Abbott’s LibreLinkUp lets Libre users share with up to 20 caregivers. The GlucoRx Vixxa 2 offers customisable threshold high and low alerts only — it does not have a predictive alert or caregiver sharing.

• •Wear length — how many days each sensor lasts
• •Cost per day — sensor price divided by wear length, not just the sticker price
• •Alerts — threshold high/low; some systems add predictive lows or caregiver sharing
• •Reading frequency — how often the sensor updates
• •India availability — whether it is officially sold and regulated here or only imported
• •Ease of use — phone app, Bluetooth, and whether you need to scan the sensor

How accurate are these CGMs?

CGM accuracy is usually described by MARD (mean absolute relative difference) — the average percentage difference between the sensor’s readings and a paired reference glucose value; a lower percentage means readings sit closer to the reference. Before comparing numbers, one caveat matters: MARD figures from different studies are not directly comparable, because they use different protocols, reference methods and patient populations, so the same device can post different MARDs in different studies.

With that in mind, the reported figures sit in a narrow band: Dexcom G7 about 8.2% (peer-reviewed), FreeStyle Libre 2 Plus about 8.2% (manufacturer/ADA), GlucoRx Vixxa 2 8.66% (manufacturer clinical data) and Sinocare iCan i3 8.71% (manufacturer). BeatO and Ultrahuman M1 do not publish a comparable MARD figure. All of the published numbers fall within roughly half a percentage point of one another and come from different studies, so they are effectively indistinguishable in everyday use — treat them as a band, not a ranking. The Vixxa 2 figure of 8.66% is from GlucoRx’s manufacturer clinical data; we did not find an independent peer-reviewed study for it.

Is a CGM right for you if you have type 2 diabetes?

Clinical bodies see a clear role for CGM where lows are a concern. The ADA states that continuous glucose monitoring is beneficial and recommended for people at high risk of hypoglycaemia, and NICE, in its type 1 diabetes guidance (NG17), offers adults a choice of CGM with the frequency, awareness and severity of hypoglycaemia among the factors considered. These are clinical positions, not a promise about your own results.

Whether a CGM suits you — and which one — is a decision to make with your doctor or diabetes care team, especially if you take insulin or other medicines that can cause low glucose. The GlucoRx Vixxa 2 is indicated for adults aged 18 and over with type 1 or type 2 diabetes and is CDSCO-licensed for import in India; GlucoRx reports over 150,000 Vixxa 2 sensors sold in India. It is worth keeping a blood glucose meter for confirmatory checks whichever CGM you choose.

A CGM is a monitoring aid, not a treatment. It does not prevent or treat low blood sugar, and it does not treat, cure or reverse diabetes. If you experience low blood sugar, follow your doctor’s advice and treatment plan. Individual results vary and this page is not a substitute for medical advice.